 |
|
|
Ryan White Care Hepatitis C & B Language
|
NATAP Webinars:
|
|
Check Back Soon for Our 2026 Webinars
|
View all archived NATAP webinars here
|
 |
Current HIV Articles and News Updates |
|
|
|
|
|
 |
Current Hepatitis C and B Articles |
|
| |
|
|
| |
|
|
|
| |
|
| |
|
|
| |
|
- HBV Patient Declaration of Rights -
- AASLD: Impact of Baseline HBeAg Status on HBV Outcomes in the ALLIANCE Study - (11/24/25)
- AASLD: Characterization of HIV/HBV Co-infected Participants Achieving High Rates of Hepatitis B Surface Antigen (HBsAg) Loss in the ALLIANCE Phase 3 Clinical Study - (11/24/25)
- AASLD: Sustained Reduction of HBV Antigen Levels During the 8-Week Follow-up Period in Treatment-Naïve (TN) or Currently-Not-Treated (CNT) HBeAg-Positive Subjects with Chronic Hepatitis B Virus
Infection After 96-Week 300 mg ALG-000184, With or Without Entecavir (ETV)
- (11/24/25)
- AASLD: Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of AB-101, a small molecule PD-L1 inhibitor, in chronic hepatitis B (CHB) subjects - (11/24/25)
- AASLD: Capsid Assembly Modulator ALG-001075 Prevents cccDNA Formation and HBV DNA Integration In Vitro - (11/24/25)
- AASLD: Analysis of Immune Responses in HIV/HBV Co-Infected Participants Experiencing HBsAg Loss After TDF/TAF-Based Antiviral Therapy in the ALLIANCE Clinical Study - (11/24/25)
- AASLD: Metabolic comorbidities and the risk of liver-related events in individuals with hepatitis B virus infection - (11/24/25)
- AASLD:
Safety, Tolerability, Immunogenicity, and Antiviral Efficacy of GS-2829 and GS-6779, a Novel, Arenaviral-Vectored, Therapeutic Hepatitis B Vaccine: Results From a Phase 1b Study in Virally Suppressed Patients With Chronic Hepatitis B - (11/24/25)
- AASLD:
Retrospective analysis of B-Clear study HBsAg levels with the ultrasensitive Lumipulse HBsAg iTACT assay and association with response and relapse - (11/24/25)
- AASLD: Up to 12 months' durability of functional cure with bepirovirsen plus Peg-IFN sequential therapy in B-Together responders: B-Sure study - (11/24/25)
- AASLD:
The Dawn of a Cure for HBV, HBV Drug Pipeline
- (11/24/25)
- AASLD:
What Are the Major Barriers to Hepatitis B Elimination and How to Overcome Them, Expanded AASLD HBV Guidelines - (11/24/25)
- AASLD:
Oral Once-Daily 300 mg ALG-000184, a Novel Capsid Assembly Modulator, Demonstrated Profound and Sustained Suppression of HBV DNA to < 10 IU/mL in All Treatment-Naïve (TN) or Currently-Not-Treated (CNT) Subjects with Chronic HBV Infection - (11/24/25)
- AASLD: Chronic hepatitis B virus infected participants responding to prior BRII-179 treatment achieved higher rate of sustained hepatitis B virus surface antigen loss on elebsiran plus peginterferon-alfa: Follow-up data from ENSURE study - (11/24/25)
- AASLD: Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of AB-101, a small molecule PD-L1 inhibitor, in chronic hepatitis B (CHB) subjects - (11/24/25)
- AASLD: Imdusiran (AB-729) is safe and well tolerated after repeat dosing in chronic hepatitis B patients: An integrated safety analysis of Phase 1 and 2 imdusiran clinical trials - (11/24/25)
- AASLD: HBsAg declines observed with VRON-0200 alone are rapidly enhanced with the addition of combination antiviral therapies: results from a Phase 1b study for functional cure in chronically HBV-infected patients - (11/24/25)
- AASLD:
Exposure to tenofovir alafenamide and tenofovir disoproxil fumarate and the risk of hepatocellular carcinoma - (11/24/25)
More Hep B Articles...
- AASLD: HU6 Oral Investigational Therapy Reduces Liver Fat and Improves Adiposity Markers in Adults with MASH: Topline Results from a Phase 2 Randomized Placebo-Controlled Trial (M-ACCEL) - (11/16/25)
- AASLD: Impact of MASLD on the development of hepatocellular carcinoma after HCV cure in patients with chronic hepatitis C: A large-scale, multicenter cohort study - (11/16/25)
More Fatty Liver Articles...
|
|
|
|
|
|
|
|
|
| | |
